跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DANTROLENE SODIUM FOR INJECTION, USP - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
DANTROLENE SODIUM FOR INJECTION, USP
Authorized
STANDARD
DANTROLENE SODIUM FOR INJECTION, USP
hikma canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ebaabf9e7c0dd9f4
Company
hikma canada limited
Type
Standard
Approval Details
Approval Id
ebaabf9e7c0dd9f4
Drug Approval Canada Name
DANTROLENE SODIUM FOR INJECTION, USP
Product Name
DANTROLENE SODIUM FOR INJECTION, USP
Status
Marketed
Status Date
2023-03-29
Original Market Date
2023-03-29
Din
02529998
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Prescription
Ahfs
12:20.08
Atc Original
M03CA01 DANTROLENE
Atc Name
m 03 ca 01
Aig Number
0109855003
Company Name
hikma canada limited
Company Address
5995 Avebury Road, Suite 804, Mississauga, Ontario, Canada, L5R 3P9
Active Ingredients
DANTROLENE SODIUM
20 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ebaabf9e7c0dd9f4
Type
Standard
Back to Health Canada Approvals